VH4524184
Small molecule
Evidence outlook · result unclear
NCT06214052 · HIV Infections
The lead study's results are posted but do not establish a clear outcome on its primary endpoint, so this tier describes the design, not an outcome; the rationale below says what the study found.
NCT06214052: The study was randomized and double-blind with matching placebo, but it was very small, with 6, 6, and 7 participants receiving VH4524184 doses and only 3 receiving placebo. Its primary endpoint was a surrogate measure of plasma HIV-1 RNA change, and although the reported mean changes favored the medium and high doses, statistical significance was not reported.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06214052 NCT06214052 · HIV Infections The study was randomized and double-blind with matching placebo, but it was very small, with 6, 6, and 7 participants receiving VH4524184 doses and only 3 receiving placebo. Its primary endpoint was a surrogate measure of plasma HIV-1 RNA change, and although the reported mean changes favored the medium and high doses, statistical significance was not reported. Registry: NCT06214052 | 2 | Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10) 2024-06-12 | Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): VH4524184 Dose 1 -1.17 Copies per milliliter (copies/mL) (Standard Deviation 0.46) | VH4524184 Dose 2 -2.15 Copies per milliliter (copies/mL) (Standard Deviation 0.254) | VH4524184 Dose 3 -2.31 Copies per milliliter (copies/mL) (Standard Deviation 0.463) vs Placebo -0.28 Copies per milliliter (copies/mL) (Standard Deviation 0.37) | Partial signal | link ↗ |
View 2 more trials
NCT07202546 NCT07202546 · HIV Infections Registry: NCT07202546 | 2 | Percentage of Participants Achieving Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Suppression (<50 copies/millilitre) as per FDA Snapshot Methodology (At Month 12) 2027-10-28 | In progress: results expected 11 Jun 2027 | not yet graded | link ↗ |
NCT05631704 NCT05631704 · HIV Infections The study randomly assigned healthy volunteers to VH4524184 or matching placebo and kept both participants and staff blinded to treatment, which is a solid design. It measured safety and drug-level readings rather than a disease outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Registry: NCT05631704 | 1 | Part 1: Number of participants with serious adverse events (SAE) and non-serious adverse events (non-SAE) (Up to 4 weeks); Part 2: Number of participants with SAE and non-SAE (Up to 6.5 weeks); Part 3: Number of participants with SAE and non-SAE (Up to 6.5 weeks); Part 1: Number of participants with adverse events based on severity (Up to 4 weeks); Part 2: Number of participants with adverse events by severity (Up to 6.5 weeks); Part 3: Number of participants with adverse events based on severity (Up to 6.5 weeks); Part 1: Percentage of participants who discontinue treatment due to adverse events (AE) (Up to 4 weeks); Part 2: Percentage of participants who discontinue treatment due to AE (Up to 6.5 weeks); Part 3: Percentage of participants who discontinue treatment due to AE (Up to 6.5 weeks); Part 1: Change from Baseline in Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Alkaline phosphatase (ALP) (International units per liter) (Baseline (Day 1) and up to 4 weeks); Part 2: Change from Baseline in AST, ALT and ALP (International units per liter) (Baseline (Day 1) and up to 6.5 weeks); Part 3: Change from Baseline in AST, ALT and ALP (International units per liter) (Baseline (Day 1) and up to 6.5 weeks); Part 1: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter) (Baseline (Day 1) and up to 4 weeks); Part 2: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter) (Baseline (Day 1) and up to 6.5 weeks); Part 3: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter) (Baseline (Day 1) and up to 6.5 weeks); Part 1: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds) (Baseline (Day 1) and up to 4 weeks); Part 2: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds) (Baseline (Day 1) and up to 6.5 weeks); Part 3: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds) (Baseline (Day 1) and up to 6.5 weeks); Part 1: Change from Baseline in International normalized ratio (INR) (Ratio) (Baseline (Day 1) and up to 4 weeks); Part 2: Change from Baseline in INR (Ratio) (Baseline (Day 1) and up to 6.5 weeks); Part 3: Change from Baseline in INR (Ratio) (Baseline (Day 1) and up to 6.5 weeks); Part 1: Number of participants with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INR (Baseline (Day 1) and up to 4 weeks); Part 2: Number of participants with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INR (Baseline (Day 1) and up to 6.5 weeks); Part 3: Number of participant with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INR (Baseline (Day 1) and up to 6.5 weeks); Part 1: Area under the plasma-concentration time curve from zero (pre-dose) extrapolated to infinite time (AUC[0-infinity]) following dosing of VH4524184 (Up to 4 weeks); Part 2: Area under the plasma concentration-time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-tau]) following dosing of VH4524184 (Up to 6.5 weeks); Part 1: Maximum observed plasma drug concentration (Cmax) following dosing of VH4524184 (Up to 4 weeks); Part 2: Cmax following dosing of VH4524184 (Up to 6.5 weeks); Part 1: Time to maximum observed plasma drug concentration (tmax) following dosing of VH4524184 (Up to 4 weeks); Part 2: Tmax following dosing of VH4524184 (Up to 6.5 weeks); Part 1: Apparent terminal half-life (t1/2) following dosing of VH4524184 (Up to 4 weeks); Part 2: T1/2 following dosing of VH4524184 (Up to 6.5 weeks) 2023-07-27 | 44 adverse events were reported in 29 participants, most of them mild (grade 1) and not drug-related. Exposures increased dose-proportionally after single doses of 10 to 300 mg, with no further increase after 460 mg single or 480 mg multiple doses. Impact on the pharmacokinetics of CYP3A substrates was minimal, with ratios of 0.8 to 1.2, and accumulation after repeat dosing ranged from 1.3- to 1.9-fold. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other HIV integrase drugs
Bictegravir, Bictegravir/lenacapavir (Bixlenvo), Cabotegravir (Apretude), Cabotegravir/rilpivirine (Cabenuva), Dolutegravir and 3 more. Compare all 9 HIV integrase drugs
This mechanism is crowded: 8 other tracked programmes target it, 8 of them ahead of this one.
This drug's own stage for HIV: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| VH4524184: this drug | Phase 2 | Small molecule | HIV integrase | Partial signal | NCT06214052: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): VH4524184 Dose 1 -1.17 Copies per milliliter (copies/mL) (Standard Deviation 0.46) | VH4524184 Dose 2 -2.15 Copies per milliliter (copies/mL) (Standard Deviation 0.254) | VH4524184 Dose 3 -2.31 Copies per milliliter (copies/mL) (Standard Deviation 0.463) vs Placebo -0.28 Copies per milliliter (copies/mL) (Standard Deviation 0.37) | |
| Amprenavir | ApprovedUS marketing discontinued | Small molecule | HIV protease | not yet graded | No reviewed efficacy summary in this indication | |
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | Reliable signal | NCT03110380: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis). NCT02607956: Week 48 HIV-1 RNA <50 copies/mL: 89.4% B/F/TAF vs 92.9% DTG + F/TAF; difference -3.5 percentage points (95.002% CI -7.9 to 1.0); prespecified non-inferiority margin 12%. | |
| Bictegravir / Lenacapavir (Bixlenvo) | Approved | Small molecule | HIV integrase, HIV capsid | Partial signal | NCT05502341: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). | |
| Cabotegravir (Apretude) | Approved | Small molecule | HIV integrase | Reliable signal | NCT02720094: Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.): Cabotegravir 13/2280 vs TDF/FTC 39/2281 | |
| Cabotegravir / Rilpivirine (Cabenuva) | Approved | Small molecule | HIV integrase, HIV reverse transcriptase | Weak signal | NCT03299049: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). NCT02938520: Virologic failure (HIV-1 RNA >=50 copies/mL, FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 4 weeks vs abacavir/dolutegravir/lamivudine: 2.1% vs 2.5%, adjusted difference -0.4% (95% CI -2.8 to 2.1); non-inferior against the 6% margin (CT.gov posted results). | |
| Darunavir (Prezista) | Approved | Small molecule | HIV protease | Partial signal | NCT00110877: HIV RNA <400 copies/mL at Week 48 (per-protocol population): darunavir-ritonavir 77% (220/286) vs lopinavir-ritonavir 68% (199/293); estimated difference 9% (95% CI 2-16). | |
| Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | Small molecule | HIV integrase | Reliable signal | NCT01263015: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003). NCT01449929: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 (Week 48): DTG 50 mg QD 90% vs DRV 800 mg + RTV 100 mg QD 83% | |
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | Reliable signal | NCT02403674: Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). NCT02275780: Week 48 HIV-1 RNA <50 copies/mL: 83.8% doravirine vs 79.9% darunavir/ritonavir; treatment difference 3.913 percentage points (95% CI -1.590 to 9.415), non-inferiority margin -10 percentage points. | |
| Doravirine / Islatravir (Idvynso) | Approved | Small molecule | HIV reverse transcriptase, HIV-1 Reverse Transcriptase | Partial signal | NCT05630755: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results). NCT04233879: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 (Week 48): Group 1: DOR/ISL 88.9% vs Group 2: BIC/FTC/TAF 88.3% | |
| Elvitegravir (Stribild) | Approved | Small molecule | HIV integrase | Partial signal | NCT01095796: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1% | |
| Emtricitabine (Emtriva) | Approved | Small molecule | HIV reverse transcriptase | Partial signal | NCT00112047: Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants | |
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase | Partial signal | NCT00323544: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm. | |
| Etravirine (Intelence) | Approved | Small molecule | HIV reverse transcriptase | Reliable signal | NCT00254046: Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 NCT00255099: Confirmed viral load <50 copies/mL at Week 24 (intention to treat): etravirine (TMC125) 62% (183/295) vs placebo 44% (129/296); difference 18% (95% CI 11-26; p=0.0003). | |
| Fostemsavir (Rukobia) | Approved | Small molecule | HIV gp120 | Partial signal | NCT02362503: Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort (Day 1 and Day 8): Randomized Cohort-fostemsavir 600 mg BID -0.791 Log10 copies per milliliter (c/mL) (95% CI -0.885 to -0.698) vs Randomized Cohort-Placebo -0.166 Log10 copies per milliliter (c/mL) (95% CI -0.326 to -0.007) NCT01384734: HIV-1 RNA < 50 copies/mL at Week 24: fostemsavir 400 mg BID 80% (95% CI 66.3 to 90), 800 mg BID 69% (54.6 to 81.7), 600 mg QD 76% (62.5 to 87.2) and 1200 mg QD 72% (57.5 to 83.8) vs the atazanavir/ritonavir reference arm 75% (60.4 to 85.7). | |
| Ibalizumab (Trogarzo) | Approved | Monoclonal antibody | CD4 receptor | Weak signal | NCT02475629: Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF (Day 14): Open-Label Ibalizumab Plus OBR 82.5% (95% CI 67.72% to 92.66%) | |
| Lenacapavir (Sunlenca) | Approved | Small molecule | HIV capsid | Partial signal | NCT04150068: Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Cohort 1A: Lenacapavir 87.5 percentage of participants | Cohort 1B: Placebo to Lenacapavir 16.7 percentage of participants NCT04143594: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm (Week 54): Group 1: SC LEN+(F/TAF→ TAF) 90.4% vs Group 2: SC LEN + (F/TAF → BIC) 84.9% vs Group 3: Oral LEN + F/TAF 84.6% vs Group 4: B/F/TAF 92.0%; p=0.7178 (Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF), p=0.3900 (Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF), p=0.3797 (Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF) missed | |
| Lenacapavir (Yeztugo) | Approved | Small molecule | HIV capsid | Reliable signal | NCT04925752: HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025). NCT04994509: HIV incidence: 0 infections in 2,134 on twice-yearly lenacapavir (0 per 100 PY; 95% CI 0.00-0.19) vs background incidence 2.41 per 100 PY (IRR 0.00; 95% CI 0.00-0.04; P<0.001) and vs F/TDF 1.69 per 100 PY (IRR 0.00; 95% CI 0.00-0.10; P<0.001) (PURPOSE 1, NEJM 2024). | |
| Maraviroc (Selzentry / Celsentri) | Approved | Small molecule | CCR5 co-receptor | Partial signal | NCT00098293: Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population (Week 48): Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) — Less than 400 copies/mL: 61.5%; Less than 50 copies/mL: 55.8% | Maraviroc Twice Daily + CBV (DB) — Less than 400 copies/mL: 70.6%; Less than 50 copies/mL: 65.3% vs Efavirenz Once Daily + CBV (DB) — Less than 400 copies/mL: 73.1%; Less than 50 copies/mL: 69.3% | |
| Raltegravir (Isentress) | Approved | Small molecule | HIV integrase | Reliable signal | NCT00293254: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3) NCT00293267: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.7% (95% CI 71.8 to 82.9) vs Placebo + OBT 41% (95% CI 32 to 50.5) | |
| Rilpivirine (Edurant) | Approved | Small molecule | HIV reverse transcriptase | Reliable signal | NCT00540449: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%. NCT00543725: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48 (Week 48): TMC278 — Responder: 291/340; Virologic failure: 24/340; Death: 1/340; Discontinued due to AE: 8/340; Discontinued due to other reason than AE: 16/340 vs Efavirenz — Responder: 276/338; Virologic failure: 18/338; Death: 3/338; Discontinued due to AE: 21/338; Discontinued due to other reason than AE: 20/338 | |
| Somatropin (Serostim) | Approved | Protein / enzyme therapeutic | Growth hormone receptor | Partial signal | NCT00082628: Change in visceral adipose tissue area at Week 12: -32.6 cm² Serostim (n=210) vs 0.5 cm² placebo (n=74), p<0.001. phase 3 result · pivotal pending NCT01077960: Primary endpoint: mean change in trunk fat from baseline to week 12, -1.7 kg (SD 1.4; n=106; p<0.001). phase 3 result · pivotal pending | |
| Tenofovir Alafenamide / Emtricitabine (Descovy) | Approved | Small molecule | HIV reverse transcriptase | Reliable signal | NCT02842086: Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564) | |
| Tenofovir Disoproxil Fumarate (Viread) | Approved | Small molecule | HIV reverse transcriptase (RT) | Partial signal | NCT00528957: Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48 (48 weeks): Tenofovir DF 83.3 percentage of participants | Stavudine or Zidovudine 91.8 percentage of participants | All TDF 85.4 percentage of participants missed NCT00352053: Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA (Baseline to 24 Weeks): Tenofovir DF -1.58 log10 copies/mL (IQR -2.15 to -0.27) | Placebo -1.549 log10 copies/mL (IQR -2.36 to -0.34) missed | |
| Tesamorelin (Egrifta WR) | Approved | Peptide | Growth hormone-releasing hormone (GHRH) receptor | Partial signal | NCT00608023: Changes From Baseline in Fasting Blood Glucose at Week 52 (Baseline and Week 52): Tesamorelin 52 Weeks 0 mg/dL (Standard Deviation 16) missed | |
| Tipranavir (Aptivus) | Approved | Small molecule | HIV protease | Partial signal | NCT00144170: Treatment Response at Week 48 (after 48 weeks of treatment): Tipranavir(TPV)/Low Dose Ritonavir(r) 34.5% vs Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r) 15% NCT00054717: Treatment Response at Week 48 (At week 48): Tipranavir(TPV)/Low Dose Ritonavir(r) 33.8% vs Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r) 16.2% | |
| ACC017 | Phase 3 | Small molecule | HIV integrase | Partial signal | NCT06719310: The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29. | |
| Albuvirtide (Aikening) | Phase 3 | Peptide | HIV gp41 | Partial signal | NCT02369965: Primary, HIV-1 RNA <50 copies/mL at week 48 (mITT, interim analysis with 46 albuvirtide and 50 control patients at week 48): 80.4% (37/46) albuvirtide + lopinavir/ritonavir vs 66.0% (33/50) NRTIs + lopinavir/ritonavir; difference 14.4% (95% CI -3.0% to 31.9%) against a prespecified non-inferiority margin of -12%, met. | |
| Alimatravir | Phase 3 | Small molecule | HIV-1 Reverse Transcriptase | Weak signal | NCT06045507: Primary outcomes, safety (no formal efficacy test): participants with at least one adverse event 62/101 (3 mg), 69/101 (6 mg) and 66/99 (12 mg) monthly MK-8527 vs 31 on placebo; discontinuation due to an adverse event 0, 2 and 1 vs 2 (CT.gov posted results). | |
| Azvudine (FNC) | Phase 3 | Small molecule | HIV reverse transcriptase | Partial signal | NCT04109183: 符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05) | |
| Dapivirine (Dapivirine Vaginal Ring) | Phase 3 | Small molecule | HIV reverse transcriptase | Reliable signal | NCT01617096: HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007). | |
| Islatravir | Phase 3 | Small molecule | HIV-1 Reverse Transcriptase | not yet graded | No reviewed efficacy summary in this indication | |
| Islatravir / Lenacapavir | Phase 3 | Small molecule | HIV-1 Reverse Transcriptase, HIV capsid | not yet graded | No reviewed efficacy summary in this indication | |
| Semzuvolimab | Phase 3 | Monoclonal antibody | CD4 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Teropavimab | Phase 3 | Monoclonal antibody | HIV envelope | not yet graded | No reviewed efficacy summary in this indication | |
| Zinlirvimab | Phase 3 | Monoclonal antibody | HIV envelope | not yet graded | No reviewed efficacy summary in this indication | |
| Elsulfavirine (Elpida) | Phase 2/3 | Small molecule | HIV reverse transcriptase | Partial signal | No reviewed efficacy summary in this indication | |
| Leronlimab | Phase 2/3 | Monoclonal antibody | CCR5 co-receptor | Weak signal | NCT02483078: Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period (From baseline visit to week 1 visit): PRO 140 — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 64%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 36% | Placebo — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 23%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 77% NCT02859961: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure (From T1 (first treatment administration) to week 48 (T48).): Part 1 - 350 mg Weekly Injections of PRO 140, Group A 23% | Part 1 - 525 mg Weekly Injections of PRO 140, Group B 43% | Part 1 - 700 mg Weekly Injections of PRO 140, Group C 45% | |
| Ulonivirine | Phase 2/3 | Small molecule | HIV reverse transcriptase | Weak signal | Featured results are safety only in this race | |
| 10-1074 | Phase 2 | Monoclonal antibody | HIV envelope | Weak signal | Featured results are safety only in this race | |
| 3BNC117 | Phase 2 | Monoclonal antibody | HIV envelope | Partial signal | NCT03041012: Co-primary 1, plasma HIV-1 RNA decay rate, ART+romidepsin+3BNC117 vs ART only: daily decay 16.9% (95% CI -27.3% to -4.93%) vs 10.0% (95% CI -14.9% to -4.86%) from day 10 to 24 (P=0.048); comparable from day 0 to 10 and day 24 to 90, met. Co-primary 2, change in intact HIV-1 provirus frequency from baseline to day 365: all groups decreased, with no significant differences between the groups, missed. | |
| CL-197 | Phase 2 | Small molecule | HIV reverse transcriptase | Weak signal | No reviewed efficacy summary in this indication | |
| Dezecapavir | Phase 2 | Small molecule | HIV capsid | Partial signal | NCT06039579: Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969) | |
| Envafolimab | Phase 2 | Monoclonal antibody | PD-L1 | Weak signal | No reviewed efficacy summary in this indication | |
| HTI Vaccine (ChAdOx1.HTI / MVA.HTI) | Phase 2 | Vaccine | HIV-1 conserved epitopes (HTI) | Partial signal | NCT03204617: Primary, safety (grade 3 or 4 local and systemic reactions; no formal efficacy test): adverse events were mostly mild and transient, with no related serious adverse events. Secondary: HTI vaccines induced strong, broad CD4 and CD8 T-cell responses; all participants had detectable viral rebound during treatment interruption. | |
| Lipovirtide | Phase 2 | Peptide | HIV gp41 | Partial signal | No reviewed efficacy summary in this indication | |
| Lotivibart | Phase 2 | Monoclonal antibody | HIV envelope | Weak signal | NCT04871113: Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69) | |
| TMB-365 / TMB-380 | Phase 2 | Combination | CD4; HIV envelope | not yet graded | No reviewed efficacy summary in this indication | |
| Trosunilimab | Phase 2 | Monoclonal antibody | α4β7 integrin | Partial signal | Featured results are safety only in this race | |
| Vesatolimod | Phase 2 | Small molecule | Toll-like receptor 7 (TLR7) (agonist) | Weak signal | Featured results are safety only in this race | |
| VH4004280 (VH-280) | Phase 2 | Small molecule | HIV capsid | Partial signal | NCT06039579: Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11): Part 1a: VH4004280 Dose Level 1 — Baseline (Day 1): 5.004 log10 c/mL (Standard Deviation 0.4592); Maximum change compared to Baseline (Day 1): -1.056 log10 c/mL (Standard Deviation 0.4567) | Part 1a: VH4004280 Dose Level 2 — Baseline (Day 1): 4.923 log10 c/mL (Standard Deviation 0.5428); Maximum change compared to Baseline (Day 1): -1.391 log10 c/mL (Standard Deviation 0.6986) | Part 2a: VH4004280 Pre-specified Dose — Baseline (Day 1): 4.866 log10 c/mL (Standard Deviation 0.7696); Maximum change compared to Baseline (Day 1): -1.983 log10 c/mL (Standard Deviation 0.2171) vs Matching Placebo for VH4004280 — Baseline (Day 1): 4.636 log10 c/mL (Standard Deviation 0.6641); Maximum change compared to Baseline (Day 1): -0.07 log10 c/mL (Standard Deviation 0.0574) | |
| JL18008 | Phase 1/2 | Protein / enzyme therapeutic | IL-7 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| LP-98 | Phase 1/2 | Peptide | HIV gp41 | Partial signal | No reviewed efficacy summary in this indication | |
| AGT103-T | Phase 1 | Gene therapy / editing | HIV proviral reservoir / autologous T cells | Weak signal | Featured results are safety only in this race | |
| Ainuovirine | Phase 1 | Small molecule | HIV reverse transcriptase | Weak signal | Featured results are safety only in this race | |
| AV000103A (ICVAX) | Phase 1 | Vaccine | HIV antigens | Weak signal | Featured results are safety only in this race | |
| BNT168 | Phase 1 | Vaccine | HIV antigens | not yet graded | No reviewed efficacy summary in this indication | |
| BNT351 | Phase 1 | Monoclonal antibody | HIV envelope | not yet graded | No reviewed efficacy summary in this indication | |
| CPT31 | Phase 1 | Peptide | HIV gp41 | Weak signal | Featured results are safety only in this race | |
| MGD014 | Phase 1 | Multispecific antibody | HIV envelope gp120 x CD3 | Weak signal | Featured results are safety only in this race | |
| MGD020 | Phase 1 | Multispecific antibody | HIV envelope gp41 x CD3 | Weak signal | Featured results are safety only in this race | |
| MK-4646 | Phase 1 | Small molecule | — | Weak signal | No reviewed efficacy summary in this indication | |
| UVAX-1107 | Phase 1 | Vaccine | HIV envelope | not yet graded | No reviewed efficacy summary in this indication | |
| VH4770359 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Islatravir / Ulonivirine | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| YASO GEL | —(overall) | Small molecule | HIV gp120 | not yet graded | No reviewed efficacy summary in this indication | |
| Fosamprenavir (Lexiva / Telzir) | Discontinued | Small molecule | HIV protease | Partial signal | NCT00450580: Percentage of Participants With HIV-1 RNA <400 and >=400 Copies/mL Over 48 Weeks (Week 48): FPV/RTV 1400/100 mg Once Daily (QD) + ABC/3TC FDC 600/300 mg Q — HIV-1 RNA <400 copies/mL: 81%; HIV-1 RNA >=400 copies/mL: 19% | FPV/RTV 700/100 mg BID + ABC/3TC FDC 600/300 mg QD — HIV-1 RNA <400 copies/mL: 82%; HIV-1 RNA >=400 copies/mL: 18% NCT00363142: Percentage of Participants Not Meeting the Definition of Virologic Failure at or Prior to Week 24 (Week 24): FPV/r100 92.1% | FPV/r200 94.2% | |
| VH4527079 | Discontinued | Multispecific antibody | HIV entry | not yet graded | No reviewed efficacy summary in this indication | |
| Zegruvirimat | Discontinued | Small molecule | HIV-1 Gag maturation (CA-SP1 cleavage) | Partial signal | NCT06061081: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA). (From Day 1 to Day 8): VH3739937 Low Dose Group -116909.43 copies/milliliter (c/mL) (Standard Deviation 187489.611) | VH3739937 Medium Dose Group -130461.67 copies/milliliter (c/mL) (Standard Deviation 106486.489) | VH3739937 High Dose Group -126026.67 copies/milliliter (c/mL) (Standard Deviation 190725.475) vs Placebo Once Daily (QD) -428000 copies/milliliter (c/mL) | Placebo Single Dose (SD) -14200 copies/milliliter (c/mL) |
Compare side by side
2 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow VH4524184 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.